Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01691521
Registration number
NCT01691521
Ethics application status
Date submitted
20/09/2012
Date registered
24/09/2012
Titles & IDs
Public title
Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma
Query!
Scientific title
MEA115588 A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma
Query!
Secondary ID [1]
0
0
115588
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Asthma
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Asthma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Mepolizumab IV
Treatment: Drugs - Mepolizumab SC
Treatment: Drugs - IV Placebo
Treatment: Drugs - SC Placebo
Experimental: Mepolizumab IV - Mepolizumab 75 mg will be administered intravenously approximately every 4 weeks with the last dose at week 32. Subjects in the Mepolizumab IV arm will receive mepolizumab 75 mg intravenously and placebo SC once every 4 weeks with the last dose at Week 28 (total of 8 doses)
Experimental: Mepolizumab SC - Subjects in the Mepolizumab SC arm will receive mepolizumab 100 mg SC and placebo IV once every 4 weeks with the last dose at Week 28 (total of 8 doses)
Placebo comparator: Placebo - Subjects in the Placebo arm will receive matching placebo SC and placebo IV once every 4 weeks with the last dose at Week 28 (total of 8 doses)
Treatment: Drugs: Mepolizumab IV
Mepolizumab 75 mg IV will be administered every 4 weeks with the last dose at Week 28
Treatment: Drugs: Mepolizumab SC
Mepolizumab 100 mg SC will be administered every 4 weeks with the last dose at Week 28
Treatment: Drugs: IV Placebo
Normal saline (placebo) will be administered IV every 4 weeks with the last dose at Week 28
Treatment: Drugs: SC Placebo
Normal saline (placebo) will be administered SC every 4 weeks with the last dose at Week 28
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Clinically Significant Exacerbations of Asthma Per Year
Query!
Assessment method [1]
0
0
Clinically significant exacerbations of asthma are defined as worsening of asthma which required use of systemic corticosteroids (IV or oral steroid like prednisone, for at least 3 days or a single intramuscular (IM) corticosteroid (CS) dose is required. For maintenance of systemic corticosteroids, at least double the existing maintenance dose for at least 3 days was required) and/or hospitalization and/or emergency department (ED) visits. The frequency of clinically significant exacerbations of asthma over the 32-week treatment period is expressed as the number of exacerbations per year. Analysis of the number of exacerbations performed using a negative binomial model with covariates of treatment group, baseline maintenance OCS therapy (OCS vs. no OCS), region, exacerbations in the year prior to the study (as an ordinal variable) and baseline % predicted FEV1, and with logarithm of time on treatment as an offset variable.
Query!
Timepoint [1]
0
0
From randomization (Week 0) to Week 32 or if Early Withdrawal (EW) 4 weeks post last dose
Query!
Secondary outcome [1]
0
0
Number of Clinically Significant Exacerbations Requiring Hospitalization (Including Intubation and Admittance to an Intensive Care Unit [ICU]) or ED Visits Per Year
Query!
Assessment method [1]
0
0
Clinically significant exacerbations of asthma are defined as worsening of asthma which required use of systemic corticosteroids (IV or oral steroid like prednisone, for at least 3 days or a single intramuscular (IM) corticosteroid (CS) dose is required. For maintenance of systemic corticosteroids, at least double the existing maintenance dose for at least 3 days was required) and/or hospitalization and/or emergency department (ED) visits. The frequency of clinically significant exacerbations of asthma over the 32-week treatment period is expressed as the number of exacerbations per year. Analysis of the number of exacerbations performed using a negative binomial model with covariates of treatment group, baseline maintenance OCS therapy (OCS vs. no OCS), region, exacerbations in the year prior to the study (as an ordinal variable) and baseline % predicted FEV1, and with logarithm of time on treatment as an offset variable.
Query!
Timepoint [1]
0
0
From randomization (Week 0) to Week 32 or if Early Withdrawal (EW) 4 weeks post last dose
Query!
Secondary outcome [2]
0
0
Number of Clinically Significant Exacerbations Requiring Hospitalization (Including Intubation and Admittance to an ICU) Per Year
Query!
Assessment method [2]
0
0
Clinically significant exacerbations of asthma is defined as worsening of asthma which required use of systemic corticosteroids (IV or oral steroid like prednisone, for at least 3 days or a single intramuscular (IM) corticosteroid (CS) dose is required. For maintenance of systemic corticosteroids, at least double the existing maintenance dose for at least 3 days was required) and/or hospitalization. The frequency of clinically significant exacerbations of asthma over the 32-week treatment period is expressed as the number of exacerbations per year. Analysis of the number of exacerbations performed using a negative binomial model with covariates of treatment group, baseline maintenance OCS therapy (OCS vs. no OCS), region, exacerbations in the year prior to the study (as an ordinal variable) and baseline % predicted FEV1, and with logarithm of time on treatment as an offset variable.
Query!
Timepoint [2]
0
0
From randomization (Week 0) to Week 32 or if Early Withdrawal (EW) 4 weeks post last dose
Query!
Secondary outcome [3]
0
0
Mean Change From Baseline in Clinic Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 32
Query!
Assessment method [3]
0
0
FEV1 is defined as the volume of air expelled from the lungs in 1 second. Pre-bronchodilator FEV1 measurements were taken by spirometry. The change from Baseline is defined as the difference between the value of the endpoint at the time point of interest and the baseline value. Analysis performed using mixed model repeated measures with covariates of baseline, region, baseline maintenance OCS therapy (OCS vs. no OCS), exacerbations in the year prior to the study (as an ordinal variable), treatment and visit, plus interaction terms for visit by baseline and visit by treatment group.
Query!
Timepoint [3]
0
0
Baseline, Week 32
Query!
Secondary outcome [4]
0
0
Mean Change From Baseline in the St. George's Respiratory Questionnaire Total Score at Week 32
Query!
Assessment method [4]
0
0
The St. George's Respiratory Questionnaire is an established instrument, comprising 50 questions, evaluating symptoms, activity, and impacts; to measure Quality of Life in participants with diseases of airway obstruction and to elicit the participant's opinion of his/her health. The lowest possible value is zero and the highest possible value is 100. The higher values correspond to greater impairment in quality of life. The questionnaire was administered at Baseline (Visit 2) and at the Exit Visit (approximately 4 weeks after the last dose of study treatment). The change from baseline is defined as the difference between the value of the endpoint at the time point of interest and the baseline value. Analysis performed using analysis of covariance with covariates of baseline, region, baseline maintenance OCS therapy (OCS vs. no OCS), exacerbations in the year prior to the study (as an ordinal variable), baseline % predicted FEV1, and treatment.
Query!
Timepoint [4]
0
0
Baseline, Week 32
Query!
Eligibility
Key inclusion criteria
* Able to give written informed consent prior to participation in the study
* At least 12 years of age at visit 1 and a minimum weight of 45 kilogram (kg)
* A well-documented requirement for regular treatment with high dose inhaled corticosteroid (ICS) in the 12 months prior to Visit 1 with or without maintenance oral corticosteroids (OCS)
* Current treatment with an additional controller medication, besides ICS, for at least 3 months or a documented failure in the past 12 months of an additional controller medication for at least 3 successive months
* Prior documentation of eosinophilic asthma or high likelihood of eosinophilic asthma
* At Visit 1, a pre-bronchodilator FEV1 <80% (for subjects >= 18 years of age), a pre-bronchodilator FEV1 <90% or FEV1:FVC ratio <0.8 (for subjects 12-17 years of age).
* Previously confirmed history of two or more exacerbations requiring treatment with systemic CS
* Male or Eligible Female (females of childbearing potential must commit to consistent and correct use of an acceptable method of birth control)
* French subjects will be included only if either affiliated to or a beneficiary of a social security category.
Query!
Minimum age
12
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Current smokers or former smokers with a smoking history of >=10 pack years
* Presence of a known pre-existing, clinically important lung condition other than asthma
* A current malignancy or previous history of malignancy in less than 12 months
* Known, pre-existing, unstable liver disease cirrhosis and known biliary abnormalities
* Known, pre-existing severe or clinically significant cardiovascular disease
* known, pre-existing other concurrent clinically significant medical conditions that are uncontrolled with standard treatment
* Subjects with any eosinophilic diseases
* QTc(F) =450msec or QTc(F) =480 msec
* A history of alcohol/substance abuse
* Subject with known immunodeficiency
* Subjects who have received omalizumab within 130 days of Visit 1 or any monoclonal antibody (other than Xolair) to treat inflammatory disease within 5 half-lives of Visit 1
* Subjects who have received treatment with an investigational drug within the past 30 days or five terminal phase half-lives of the drug whichever is longer
* Subjects with allergy/intolerance to a monoclonal antibody or biologic.
* Subjects who are pregnant or breastfeeding
* Subjects who have known evidence of lack of adherence to controller medications and/or ability to follow physician's recommendations
* Previously participated in any study with mepolizumab and received investigational product (including placebo)
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
8/10/2012
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
18/01/2014
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
580
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
GSK Investigational Site - New Lambton
Query!
Recruitment hospital [2]
0
0
GSK Investigational Site - Bedford Park
Query!
Recruitment hospital [3]
0
0
GSK Investigational Site - Clayton
Query!
Recruitment hospital [4]
0
0
GSK Investigational Site - Nedlands
Query!
Recruitment hospital [5]
0
0
GSK Investigational Site - Parkville
Query!
Recruitment postcode(s) [1]
0
0
2305 - New Lambton
Query!
Recruitment postcode(s) [2]
0
0
5042 - Bedford Park
Query!
Recruitment postcode(s) [3]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [4]
0
0
6009 - Nedlands
Query!
Recruitment postcode(s) [5]
0
0
3052 - Parkville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Connecticut
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Maryland
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Minnesota
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
New York
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
North Carolina
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Ohio
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Pennsylvania
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Tennessee
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Utah
Query!
Country [15]
0
0
Argentina
Query!
State/province [15]
0
0
Buenos Aires
Query!
Country [16]
0
0
Argentina
Query!
State/province [16]
0
0
Mendoza
Query!
Country [17]
0
0
Argentina
Query!
State/province [17]
0
0
Santa Fe
Query!
Country [18]
0
0
Argentina
Query!
State/province [18]
0
0
Ciudad Autónoma de Buenos Aires
Query!
Country [19]
0
0
Belgium
Query!
State/province [19]
0
0
Bruxelles
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Gent
Query!
Country [21]
0
0
Belgium
Query!
State/province [21]
0
0
Leuven
Query!
Country [22]
0
0
Belgium
Query!
State/province [22]
0
0
Liège
Query!
Country [23]
0
0
Canada
Query!
State/province [23]
0
0
Alberta
Query!
Country [24]
0
0
Canada
Query!
State/province [24]
0
0
British Columbia
Query!
Country [25]
0
0
Canada
Query!
State/province [25]
0
0
Manitoba
Query!
Country [26]
0
0
Canada
Query!
State/province [26]
0
0
Ontario
Query!
Country [27]
0
0
Canada
Query!
State/province [27]
0
0
Quebec
Query!
Country [28]
0
0
Chile
Query!
State/province [28]
0
0
Reg Del Libert Bern Ohiggins
Query!
Country [29]
0
0
Chile
Query!
State/province [29]
0
0
Santiago
Query!
Country [30]
0
0
Chile
Query!
State/province [30]
0
0
Talcahuano
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Le Kremlin-Bicêtre Cedex
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Lille cedex
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Lyon cedex 04
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Marseille cedex 20
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Montpellier cedex 5
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Perpignan
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Saint Pierre cedex
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Bayern
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Brandenburg
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Hessen
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Rheinland-Pfalz
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Sachsen-Anhalt
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Berlin
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Hamburg
Query!
Country [45]
0
0
Italy
Query!
State/province [45]
0
0
Campania
Query!
Country [46]
0
0
Italy
Query!
State/province [46]
0
0
Emilia-Romagna
Query!
Country [47]
0
0
Italy
Query!
State/province [47]
0
0
Liguria
Query!
Country [48]
0
0
Italy
Query!
State/province [48]
0
0
Puglia
Query!
Country [49]
0
0
Italy
Query!
State/province [49]
0
0
Toscana
Query!
Country [50]
0
0
Italy
Query!
State/province [50]
0
0
Umbria
Query!
Country [51]
0
0
Italy
Query!
State/province [51]
0
0
Veneto
Query!
Country [52]
0
0
Japan
Query!
State/province [52]
0
0
Chiba
Query!
Country [53]
0
0
Japan
Query!
State/province [53]
0
0
Fukuoka
Query!
Country [54]
0
0
Japan
Query!
State/province [54]
0
0
Gunma
Query!
Country [55]
0
0
Japan
Query!
State/province [55]
0
0
Hiroshima
Query!
Country [56]
0
0
Japan
Query!
State/province [56]
0
0
Hokkaido
Query!
Country [57]
0
0
Japan
Query!
State/province [57]
0
0
Hyogo
Query!
Country [58]
0
0
Japan
Query!
State/province [58]
0
0
Ibaraki
Query!
Country [59]
0
0
Japan
Query!
State/province [59]
0
0
Kanagawa
Query!
Country [60]
0
0
Japan
Query!
State/province [60]
0
0
Kumamoto
Query!
Country [61]
0
0
Japan
Query!
State/province [61]
0
0
Mie
Query!
Country [62]
0
0
Japan
Query!
State/province [62]
0
0
Okinawa
Query!
Country [63]
0
0
Japan
Query!
State/province [63]
0
0
Osaka
Query!
Country [64]
0
0
Japan
Query!
State/province [64]
0
0
Tokyo
Query!
Country [65]
0
0
Korea, Republic of
Query!
State/province [65]
0
0
Anyang-Si
Query!
Country [66]
0
0
Korea, Republic of
Query!
State/province [66]
0
0
Bucheon-si,
Query!
Country [67]
0
0
Korea, Republic of
Query!
State/province [67]
0
0
Cheongju, Chungcheongbuk-do
Query!
Country [68]
0
0
Korea, Republic of
Query!
State/province [68]
0
0
Daegu
Query!
Country [69]
0
0
Korea, Republic of
Query!
State/province [69]
0
0
Donggu Gwangju
Query!
Country [70]
0
0
Korea, Republic of
Query!
State/province [70]
0
0
Incheon
Query!
Country [71]
0
0
Korea, Republic of
Query!
State/province [71]
0
0
Jeonju-si, Jeollabuk-Do
Query!
Country [72]
0
0
Korea, Republic of
Query!
State/province [72]
0
0
Kangwon-do
Query!
Country [73]
0
0
Korea, Republic of
Query!
State/province [73]
0
0
Seoul
Query!
Country [74]
0
0
Korea, Republic of
Query!
State/province [74]
0
0
Suwon, Kyonggi-do
Query!
Country [75]
0
0
Mexico
Query!
State/province [75]
0
0
Jalisco
Query!
Country [76]
0
0
Mexico
Query!
State/province [76]
0
0
Nuevo León
Query!
Country [77]
0
0
Mexico
Query!
State/province [77]
0
0
México DF
Query!
Country [78]
0
0
Russian Federation
Query!
State/province [78]
0
0
Chelyabinsk
Query!
Country [79]
0
0
Russian Federation
Query!
State/province [79]
0
0
Moscow
Query!
Country [80]
0
0
Russian Federation
Query!
State/province [80]
0
0
Saint-Petersburg
Query!
Country [81]
0
0
Russian Federation
Query!
State/province [81]
0
0
St. Petersburg
Query!
Country [82]
0
0
Spain
Query!
State/province [82]
0
0
Alicante
Query!
Country [83]
0
0
Spain
Query!
State/province [83]
0
0
Barcelona
Query!
Country [84]
0
0
Spain
Query!
State/province [84]
0
0
Pozuelo De Alarcón/Madrid
Query!
Country [85]
0
0
Ukraine
Query!
State/province [85]
0
0
Kharkiv
Query!
Country [86]
0
0
Ukraine
Query!
State/province [86]
0
0
Kiev
Query!
Country [87]
0
0
Ukraine
Query!
State/province [87]
0
0
Mykolayiv
Query!
Country [88]
0
0
Ukraine
Query!
State/province [88]
0
0
Vinnytsia
Query!
Country [89]
0
0
United Kingdom
Query!
State/province [89]
0
0
Bradford
Query!
Country [90]
0
0
United Kingdom
Query!
State/province [90]
0
0
Glasgow
Query!
Country [91]
0
0
United Kingdom
Query!
State/province [91]
0
0
London
Query!
Country [92]
0
0
United Kingdom
Query!
State/province [92]
0
0
Plymouth
Query!
Country [93]
0
0
United Kingdom
Query!
State/province [93]
0
0
Southampton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
GlaxoSmithKline
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study will evaluate two dose regimens of mepolizumab \[75mg intravenous (i.v.) or 100mg subcutaneous (SC) every 4 weeks\] compared with placebo over a 32 week treatment period in subjects with severe refractory asthma with elevated blood eosinophils. Efficacy will be measured by a reduction in the frequency of asthma exacerbations. Additional efficacy assessments will include measurements of lung function, symptom scores, and quality of life. Safety will be assessed by clinical laboratory samples, ECGs, immunogenicity and adverse events. This study is intended to replicate the Phase IIb/III study MEA112997. Subjects in MEA115588, who meet all eligibility criteria at screening visit, will enter the run-in period. Those subjects that are not able/eligible to be randomised at the end of the 6 week run-in period will be deemed run-in failures. Subjects will remain on their current maintenance therapy throughout the run-in, double-blind treatment administration and follow-up periods. Subjects who meet the randomisation eligibility criteria will be randomised in a 1:1:1 ratio to receive one of the following treatments every 4 weeks for a total of 8 doses: Mepolizumab 75 miligram (mg) i.v. and placebo SC, or Mepolizumab 100 mg SC and placebo i.v. or Placebo i.v. and placebo SC. Subjects that receive all 8 doses of double-blind treatment, and meet the eligibility criteria for the Open-Label Extension (OLE) Study, will be offered the opportunity to participate in the OLE trial.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01691521
Query!
Trial related presentations / publications
Lemiere C, Taille C, Lee JK, Smith SG, Mallett S, Albers FC, Bradford ES, Yancey SW, Liu MC. Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials. Respir Res. 2021 Jun 22;22(1):184. doi: 10.1186/s12931-021-01767-z. Gibson PG, Prazma CM, Chupp GL, Bradford ES, Forshag M, Mallett SA, Yancey SW, Smith SG, Bel EH. Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions. Respir Res. 2021 Jun 7;22(1):171. doi: 10.1186/s12931-021-01746-4. Best N, Price RG, Pouliquen IJ, Keene ON. Assessing efficacy in important subgroups in confirmatory trials: An example using Bayesian dynamic borrowing. Pharm Stat. 2021 May;20(3):551-562. doi: 10.1002/pst.2093. Epub 2021 Jan 21. Wardlaw A, Howarth PH, Israel E, Taille C, Quirce S, Mallett S, Bates S, Albers FC, Kwon N. Fungal sensitization and its relationship to mepolizumab response in patients with severe eosinophilic asthma. Clin Exp Allergy. 2020 Jul;50(7):869-872. doi: 10.1111/cea.13680. Epub 2020 Jun 25. No abstract available. Kim MK, Park HS, Park CS, Min SJ, Albers FC, Yancey SW, Mayer B, Kwon N. Efficacy and safety of mepolizumab in Korean patients with severe eosinophilic asthma from the DREAM and MENSA studies. Korean J Intern Med. 2021 Mar;36(2):362-370. doi: 10.3904/kjim.2019.198. Epub 2020 May 26. Khurana S, Brusselle GG, Bel EH, FitzGerald JM, Masoli M, Korn S, Kato M, Albers FC, Bradford ES, Gilson MJ, Price RG, Humbert M. Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study. Clin Ther. 2019 Oct;41(10):2041-2056.e5. doi: 10.1016/j.clinthera.2019.07.007. Epub 2019 Aug 22. Khurana S, Lyness JM, Mallett S, Nelsen LM, Prazma CM, Albers FC, Forshag M, Llanos JP, Yancey SW, Ortega HG. Association of depressive symptoms with health status and markers of uncontrolled severe asthma. Allergy Asthma Proc. 2019 Jul 1;40(4):230-239. doi: 10.2500/aap.2019.40.4229. Nelsen LM, Cockle SM, Gunsoy NB, Jones P, Albers FC, Bradford ES, Mullerova H. Impact of exacerbations on St George's Respiratory Questionnaire score in patients with severe asthma: post hoc analyses of two clinical trials and an observational study. J Asthma. 2020 Sep;57(9):1006-1016. doi: 10.1080/02770903.2019.1630640. Epub 2019 Jun 28. Yancey SW, Bradford ES, Keene ON. Disease burden and efficacy of mepolizumab in patients with severe asthma and blood eosinophil counts of >/=150-300 cells/muL. Respir Med. 2019 May;151:139-141. doi: 10.1016/j.rmed.2019.04.008. Epub 2019 Apr 8. Ortega HG, Meyer E, Brusselle G, Asano K, Prazma CM, Albers FC, Mallett SA, Yancey SW, Gleich GJ. Update on immunogenicity in severe asthma: Experience with mepolizumab. J Allergy Clin Immunol Pract. 2019 Sep-Oct;7(7):2469-2475.e1. doi: 10.1016/j.jaip.2019.03.042. Epub 2019 Apr 5. No abstract available. Ortega H, Menzies-Gow A, Llanos JP, Forshag M, Albers F, Gunsoy N, Bradford ES, Yancey SW, Kraft M. Rapid and Consistent Improvements in Morning PEF in Patients with Severe Eosinophilic Asthma Treated with Mepolizumab. Adv Ther. 2018 Jul;35(7):1059-1068. doi: 10.1007/s12325-018-0727-8. Epub 2018 Jun 15. Ortega H, Yancey SW, Keene ON, Gunsoy NB, Albers FC, Howarth PH. Asthma Exacerbations Associated with Lung Function Decline in Patients with Severe Eosinophilic Asthma. J Allergy Clin Immunol Pract. 2018 May-Jun;6(3):980-986.e1. doi: 10.1016/j.jaip.2017.12.019. Epub 2018 Feb 15. Gunsoy NB, Cockle SM, Yancey SW, Keene ON, Bradford ES, Albers FC, Pavord ID. Evaluation of Potential Continuation Rules for Mepolizumab Treatment of Severe Eosinophilic Asthma. J Allergy Clin Immunol Pract. 2018 May-Jun;6(3):874-882.e4. doi: 10.1016/j.jaip.2017.11.026. Epub 2017 Dec 16. Albers FC, Price RG, Smith SG, Yancey SW. Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. J Allergy Clin Immunol. 2017 Nov;140(5):1464-1466.e4. doi: 10.1016/j.jaci.2017.06.010. Epub 2017 Jul 4. No abstract available. Magnan A, Bourdin A, Prazma CM, Albers FC, Price RG, Yancey SW, Ortega H. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. Allergy. 2016 Sep;71(9):1335-44. doi: 10.1111/all.12914. Epub 2016 May 24. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, Chanez P; MENSA Investigators. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014 Sep 25;371(13):1198-207. doi: 10.1056/NEJMoa1403290. Epub 2014 Sep 8. Erratum In: N Engl J Med. 2015 Apr 30;372(18):1777. doi: 10.1056/NEJMx150017.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
GSK Clinical Trials
Query!
Address
0
0
GlaxoSmithKline
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Query!
When will data be available (start and end dates)?
Query!
Available to whom?
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT01691521